Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
College of Pharmacy, Chung-Ang University, Seoul, South Korea.
Arthritis Res Ther. 2021 Oct 27;23(1):270. doi: 10.1186/s13075-021-02648-y.
This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE.
We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated.
We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6-1.9), 1.7 (95% CI 1.5-1.8), and 5.9 (95% CI 4.8-7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1-4.2), bladder (2.4, 95% CI 1.1-3.8), liver (1.9, 95% CI 1.4-2.3), pancreas (1.9, 95% CI 1.3-2.6), lung (1.8, 95% CI 1.2-2.4), colon (1.7, 95% CI 1.3-2.2), thyroid (1.6, 95% CI 1.3-1.8) and breast and reproductive system (1.5, 95% CI 1.2-1.7) cancers are at increased risk in SLE patients.
An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
本研究旨在评估韩国系统性红斑狼疮（SLE）患者的恶性肿瘤粗发病率和相对风险。
我们使用韩国国家健康保险服务数据库进行了一项回顾性全国队列研究。所有年龄在 19 岁以上的现患 SLE 患者均从 2012 年 1 月至 2014 年 12 月确定，并观察至恶性肿瘤诊断、死亡或研究结束（2015 年 12 月）。估计 SLE 患者中总体和特定部位恶性肿瘤的粗发病率（IRs）和标准化发病率比（SIRs）。
我们确定了 17854 例 SLE 患者，在观察期间（60511 人年），SLE 患者中发生了 768 例实体恶性肿瘤（126.9/10000 人年）和 68 例血液恶性肿瘤（11.2/10000 人年）。SLE 患者中以乳腺癌和生殖系统及甲状腺癌为主，其次是肝癌和结肠癌。与普通人群相比，SLE 患者的总体、实体和血液恶性肿瘤 SIR 分别为 1.8（95%置信区间 [CI] 1.6-1.9）、1.7（95% CI 1.5-1.8）和 5.9（95% CI 4.8-7.3）。在实体恶性肿瘤中，头颈部（2.7，95%CI 1.1-4.2）、膀胱（2.4，95%CI 1.1-3.8）、肝脏（1.9，95%CI 1.4-2.3）、胰腺（1.9，95%CI 1.3-2.6）、肺（1.8，95%CI 1.2-2.4）、结肠（1.7，95%CI 1.3-2.2）、甲状腺（1.6，95%CI 1.3-1.8）和乳腺癌和生殖系统（1.5，95%CI 1.2-1.7）癌症的风险增加。
与普通人群相比，韩国 SLE 患者的血液系统恶性肿瘤和实体恶性肿瘤风险增加。
